SCHEMBL2961007

SCHEMBL2961007

COc1ccccc1N1CCN(S(=O)(=O)c2ccc3ccccc3c2)CC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.80
LMNA P02545 2/20 0.77
USP2 O75604 1/20 0.77
GLA P06280 1/20 0.77
TSHR P16473 1/20 0.77
MAPK1 P28482 1/20 0.77
HSD17B10 Q99714 1/20 0.77
TP53 P04637 2/20 0.75
POLB P06746 1/20 0.75
GAA P10253 4/20 0.72
GFER P55789 2/20 0.72
ALDH1A1 P00352 2/20 0.71
KMT2A Q03164 4/20 0.69
MEN1 O00255 1/20 0.69
MAPT P10636 3/20 0.67
HTR1A P08908 3/20 0.63
ADRA2A P08913 3/20 0.63
HTT P42858 1/20 0.61
DRD2 P14416 2/20 0.61
HTR2A P28223 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23051855 0.83 SMN1; SMN2 (0.71) SMN1; SMN2LMNATSHRMAPK1KMT2A
SCHEMBL11508895 0.83 GAA (0.82) SMN1; SMN2LMNAUSP2GLATSHR
SCHEMBL3213621 0.82 PKM (0.71) SMN1; SMN2LMNAUSP2TSHRALDH1A1
SCHEMBL5255516 0.82 GAA (0.80) SMN1; SMN2LMNAUSP2GLATSHR
SCHEMBL18134604 0.81 MCOLN3 (0.83) SMN1; SMN2LMNATSHRKMT2AMEN1
SCHEMBL3212035 0.81 CTDSP1 (0.62) SMN1; SMN2LMNATSHRKMT2AMEN1
SCHEMBL11507203 0.79 GAA (0.74) SMN1; SMN2LMNAUSP2GLATSHR
SCHEMBL9312346 0.79 GAA (0.74) SMN1; SMN2LMNAUSP2GLATSHR
SCHEMBL3209949 0.79 MCOLN3 (0.58) SMN1; SMN2LMNATSHRKMT2AMEN1
SCHEMBL3219662 0.78 PKM (0.63) SMN1; SMN2LMNATSHRMAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866298-A2 HYDROXYSTEROID DEHYDROGENASE INHIBITORS Takeda San Diego, Inc. (US) 2007-12-19 EP claimed
WO-2006105127-A2 HYDROXYSTEROID DEHYDROGENASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-10-05 WO claimed
US-20060223829-A1 Hydroxysteroid dehydrogenase inhibitors TAKEDA SAN DIEGO, INC. 2006-10-05 US claimed
US-7759339-B2 Hydroxysteroid dehydrogenase inhibitors TAKEDA SAN DIEGO, INC. (US) 2010-07-20 US disclosed
US-7759339-B2 Hydroxysteroid dehydrogenase inhibitors TAKEDA SAN DIEGO, INC. (US) 2010-07-20 US disclosed
US-7759339-B2 Hydroxysteroid dehydrogenase inhibitors TAKEDA SAN DIEGO, INC. (US) 2010-07-20 US disclosed
EP-1866298-A2 HYDROXYSTEROID DEHYDROGENASE INHIBITORS Takeda San Diego, Inc. (US) 2007-12-19 EP disclosed
WO-2006105127-A2 HYDROXYSTEROID DEHYDROGENASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-10-05 WO disclosed
US-20060223829-A1 Hydroxysteroid dehydrogenase inhibitors TAKEDA SAN DIEGO, INC. 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223829-A1 Hydroxysteroid dehydrogenase inhibitors HSD17B1, HSD17B3, HSD17B2 SMN1; SMN2 4417/4885LMNA 2965/4885USP2 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.